Anokion
Anokion is a clinical-stage Swiss biotechnology company developing an immune tolerance platform, with its lead drug candidate KAN-101 in Phase 2 clinical trials for celiac disease, an autoimmune disorder with no approved pharmacological therapy.
- Company typePrivate
- Founded2010
- HeadquartersEcublens, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Anokion firmographics
Firmographics- Name
- Anokion
- Website
- https://anokion.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Anokion is a clinical-stage Swiss biotechnology company developing an immune tolerance platform, with its lead drug candidate KAN-101 in Phase 2 clinical trials for celiac disease, an autoimmune disorder with no approved pharmacological therapy.
- Ownership category
- akta.pro rank
Anokion industry classification
Industry- Product category
- Biopharmaceuticals / Immunotherapy
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Immunology & Inflammation Pharmaceuticals (HLAIAAAD)
- akta.pro secondary industry
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where Anokion is headquartered
LocationHeadquarters
- HQ city
- Ecublens
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
Anokion business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Drug Development and Commercialization: Pre-revenue clinical-stage biotechnology company developing proprietary drug candidates for autoimmune diseases. Revenue will be generated through pharmaceutical product sales upon successful clinical development and regulatory approval.
Go-to-market motion1 record
Marketing channels2 records
Anokion product offering
Product offeringCore offering
Anokion is a clinical-stage biotechnology company developing proprietary immune tolerance therapeutics for autoimmune diseases. The company's lead drug candidate, KAN-101, is in Phase 2 clinical development for the treatment of celiac disease. The platform is built around harnessing natural immune equilibrium to induce antigen-specific immune tolerance.
Differentiator
Problem solved
Functional benefit
Products and services
- KAN-101
Quantifiable outcome
- Phase 2 clinical trial enrollment for KAN-101 in celiac disease
Companies that use Anokion
Customer profileSegments2 records
Ideal customer profiles1 record
Anokion technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Anokion partnerships and signals
Strategic signalScale indicators3 records
Anokion competitors and assessment
Company assessmentBroad incumbents
- AbbVie: AbbVie is a global immunology leader (Humira, Skyrizi, Rinvoq) and a potential strategic acquirer of immune tolerance platforms like Anokion's. As a broad incumbent, it shapes competitive dynamics and M&A benchmarks for autoimmune-focused biotechs.
- Takeda Pharmaceutical: Takeda acquired PvP Biologics and is advancing TAK-062 (latiglutenase) for celiac disease. As a large pharmaceutical company with multiple celiac programs and established autoimmune infrastructure, Takeda is a broad incumbent peer to Anokion in celiac specifically.
- Pfizer: Pfizer is both a strategic investor and board participant in Anokion and a major immunology player. As a broad incumbent with autoimmune assets, Pfizer shapes both partnership economics and competitive benchmarks for celiac and adjacent indications.
- Sanofi: Sanofi operates a major immunology franchise (Dupixent) and pursues antigen-specific and immune-modulating therapies. It is comparable to Anokion as a broad incumbent competing for autoimmune patient share and as a potential strategic acquirer of platform biotechs.
Direct peers
- Selecta Biosciences: Selecta Biosciences is developing antigen-specific immune tolerance therapies using ImmTOR and SEL-302 platforms. It is directly comparable to Anokion because both pursue immune tolerance as a core platform approach to autoimmune disease.
- Immunic Therapeutics: Immunic Therapeutics is developing IMU-856 for celiac disease and has other autoimmune programs in IBD and multiple sclerosis. It is one of the closest direct comparables to Anokion in terms of indication focus, development stage, and disease-modifying mechanism.
- COUR Pharmaceuticals: COUR Pharmaceuticals develops antigen-specific immune tolerance therapies for autoimmune diseases, including celiac disease. Its platform and target indications overlap materially with Anokion's KAN-101 approach.
- 9 Meters Biopharma: 9 Meters Biopharma has been developing larazotide (NM-002) for celiac disease, a tight-junction modulator addressing the same indication as KAN-101. It is a direct competitor for celiac patients and provider attention.
Emerging players
- AnaptysBio: AnaptysBio develops antibody-based therapeutics for inflammatory and autoimmune diseases. Although it uses a different modality, it targets overlapping indications and competes for autoimmune development talent and capital relevant to Anokion's expansion roadmap.
- Provention Bio: Provention Bio develops immune-mediated disease therapies, including work in celiac and type 1 diabetes. It shares Anokion's focus on autoimmune diseases with antigen- or immune-modulating mechanisms but operates at a more commercial stage.
Market position
Customer concentration
Anokion social profiles
Digital presenceAnokion financial estimates
Financial estimateRevenue estimate
Valuation estimate
Anokion leadership team
Management profileNumber of profiles
Profiles6 records
Anokion funding detail
Funding detailFunding overview
Funding rounds4 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Anokion M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Anokion
What does Anokion do?
Anokion is a clinical-stage biotechnology company developing proprietary immune tolerance therapeutics for autoimmune diseases. The company's lead drug candidate, KAN-101, is in Phase 2 clinical development for the treatment of celiac disease. The platform is built around harnessing natural immune equilibrium to induce antigen-specific immune tolerance.
Is Anokion a public or private company?
Anokion is a private company. It is classified as venture growth investor backed and is currently operating.
When was Anokion founded?
Anokion was founded in 2010. It employs 11 to 50 people.
Where is Anokion based?
Anokion is headquartered in Ecublens, Switzerland, in the Europe region.
How does Anokion make money?
One revenue line is on record: drug Development and Commercialization.
Who are Anokion's main competitors?
Broad incumbents on record are AbbVie, Takeda Pharmaceutical, Pfizer and Sanofi. Direct peers are Selecta Biosciences, Immunic Therapeutics, COUR Pharmaceuticals and 9 Meters Biopharma. Emerging players are AnaptysBio and Provention Bio.
Does Anokion have an API?
No public API is recorded for Anokion.
What industry is Anokion in?
Anokion's product category is Biopharmaceuticals / Immunotherapy. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its SIC code is 2834.